报价延迟最少15分钟:2025/10/23 16:14 EDT
盘后时段
|
||||
|
0.6217 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.6217
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.05/--
|
|
企业价值
8.71M
|
| 资产负债 |
|
每股账面净值
0.43
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
448.20K
|
|
每股收益
--
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/10/23 16:14 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Pheton Holdings Ltd is a healthcare solutions provider dedicated to developing and commercializing treatment software and devices used for brachytherapy. Its proprietary treatment planning system is a type of radiation therapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. Its proprietary treatment planning system, FTTPS, is designed to promote the efficiency, accuracy, and safety of brachytherapy.FTTPS is a user-oriented treatment planning system, or TPS, for treating a wide variety of malignant tumors, which can determine the target volume, prescription dose, and dose limitation to protect OARs and produce a safe, effective, and accurate dose distribution plan for brachytherapy for cancer patients. |
